Grants>Oncology

Call for Applications: Alex’s Lemonade Stand Foundation Bridge & Springboard Grants

Bridge Grant

Alex’s Lemonade Stand Foundation introduces a new funding opportunity for researchers whose projects are in jeopardy due to the decreased funding available from the National Institutes of Health (NIH). ALSF’s Bridge Grants are intended to keep scientist’s projects on track while they reapply for NIH funding to ensure novel childhood cancer research projects are not compromised. ALSF’s Bridge Grant awards will provide $100,000 for 12 months to be used for supplies, personnel or the Principal Investigator’s salary.

Eligibility Requirements:

Project must have been previously funded by an NIH R01, R03, R21 or P01 Award. (R01 Supplements are not eligible for Bridge Grants.)

Researchers must have applied to the NIH for an R01 or P01 renewal for an ongoing project or to continue the project via new R01 or P01 within the last 6 months.

The application must have been scored ≤25th percentile, but outside of the agency’s fundable range.

Applicants must be reapplying for an R01 or P01 Award from the NIH within the next two NIH Grant cycles.

Projects must be aligned with ALSF’s mission, thus focused on better diagnosing or curing childhood cancers.

Funds may be used for supplies, personnel or PI’s salary and may not exceed $100,000. ALSF does not pay indirect costs. 
  
Application Process:

To expedite the application progress, ALSF’s Scientific Advisory Board will review the previously reviewed NIH application along with any changes that have been made in response to feedback from NIH reviews.

A cover letter, summary statement, response to NIH critique and budget will be required by all applicants.

All applications must be submitted via ALSF’s online application.
    
Springboard Grant

ALSF’s offers the Springboard Grant in response to cut-backs in National Institutes of Health (NIH) funding of new R01 and P01 applications. The Springboard Grant is designed to jump-start new projects with high impact potential for childhood cancer research while other funding is sought. Awards will provide $100,000 for 12 months to be used for supplies, personnel or the Principal Investigator’s salary.

Eligibility Requirements:

Researchers must have applied to the NIH for an R01 or P01 award within the last 6 months. (R01 Supplements are not eligible for Springboard Grants)

Applications must have scored ≤20%, but outside of the agency’s fundable range.

Applicants must be reapplying for an R01 or P01 award from the NIH within the next two NIH Grant cycles.

Projects must be aligned with ALSF’s mission thus focused on better diagnosing or curing childhood cancers.

Funds may be used for supplies, personnel or PI’s salary and may not exceed $100,000. ALSF does not pay indirect costs. 

Application Process:

To expedite the application progress, ALSF’s Scientific Advisory Board will review the previously reviewed NIH application along with any changes that have been made in response to feedback from NIH reviews.

A cover letter, summary statement, response to NIH critique and budget will be required by all applicants.
All applications must be submitted via ALSF’s online application.

Alex's Lemonade Stand Foundation for Childhood Cancer  333 E. Lancaster Ave., #414 Wynnewood, PA 19096

Ph: 610.649.3034

Fax: 610.649.3038

Request for Proposals: International Innovation Grant

The International Innovation Grant provides research funding in support of novel and innovative projects that can have a significant impact on cancer control in low- and middle-income countries.

The International Innovation Grant is a one-year research grant of up to $20,000 that is awarded and paid directly to a nonprofit organization or governmental agency in a low-income or middle-income country. The grant may be used by the organization only for the approved, budgeted costs of the research project. Each grant will have a Principal Investigator who is an ASCO member, is affiliated with the Grantee Organization, and is a resident of the low-income or middle-income country.

International Innovation Grants are hypothesis-driven research grants that fund a specific research project that may result in the discovery of new knowledge about how to advance cancer control in a low- or middle-income setting.  It is anticipated that novel approaches and clinical designs proposed for this grant may differ from what would be considered standard practice within high-income settings.  Grantee Organizations and Principal Investigators will be expected to share and disseminate the knowledge gained during their research project.

The online system will open for Letter of Intent submission on July 1, 2013. All Letters of Intent must be submitted by August 1, 2013.

Questions? Read our Frequently Asked Questions document:

http://www.conquercancerfoundation.org/sites/conquercancerfoundation.org/files/international_innovation_grant_faq_5-1-2013.pdf

If that doesn’t answer your question, email grants@conquercancerfoundation.org.

2014 International Innovation Grant Timeline:

May 1, 2013 RFP is Released for 2014 International Innovation Grant

July 1, 2013 Online Application System Opens for Submitting Letters of Intent

August 1, 2013 Letters of Intent Due

October 3, 2013 Invited Full Applications Due

December 2013 Grant Recipients Announced

January 1 - December 30, 2014 Grant Project Period

Request for Proposals: Hematology Oncology Pharmacy Association 2013 Research Award

The HOPA Foundation Board announces the opening of a call for proposals for the 2013 HOPA Foundation Research Award. The HOPA Foundation will fund up to 3 grants based on the stated scope of work. A total of $50,000 in funding is available to be awarded in 2013 through a competitive peer-review process described below.

Purpose

The individual award is intended to support a hematology/oncology pharmacy practice research project with subsequent publication that aligns with the strategic plan of the HOPA Foundation. Pharmacy practice is broadly defined including areas such as outcomes, surveys, patient safety, standards validation, and translational science applications. Multiple institutions may be involved in the project, and co-PI projects are allowed. The grant is open to all members of HOPA except standing members of the HOPA Foundation and HOPA Board Members.

Review

The HOPA research grants are intended to provide support for projects that are likely to result in facilitating the efforts of hematology/oncology pharmacists to optimize the care of individuals affected by cancer.

The HOPA Foundation Research Grant Review Panel will be chaired by a Foundation Board member; however its composition may vary based on the nature of the proposals received. Members will be comprised of individuals with expertise and familiarity in practice and research.

Application Process

1. A Letter of Intent (LOI) must be submitted electronically by June 14, 2013 to the attention of Susan Floutsakos at (sfloutsakos@connect2amc.com) who will act as the Grant Administrator.

2. The LOIs will be reviewed by members of the HOPA Foundation Research Grant Panel and a decision regarding acceptance for development into a full grant proposal in July 2013. Concepts presented in the LOI that do not address stated objectives and/or criteria of the RFP will be returned and not considered further with a letter of explanation.

3. Submitters of LOIs that are approved for development will be invited to prepare a full grant proposal using the current NIH format. Refer to http://grants.nih.gov/grants/funding/phs398/phs398.html for format. The grant proposals will be due by September 16, 2013. Grant applications must be submitted electronically as a single pdf file to Susan Floutsakos, (sfloutsakos@connect2amc.com) the Grant Administrator.

4. The public announcement of the awards will occur in late November 2013. All applicants will receive written feedback regarding review of their application.

Award Administration

1. Funds will be released to the investigator in their entirety, contingent upon Institutional Review Board approval, unless stipulations are placed on the disbursement by the HOPA Foundation Research Panel in its review of the application.

2. The awardee is required to submit a report of progress every six months to the HOPA Foundation Board Chair.

3. The awardee is expected to present the results of their research at the HOPA annual meeting. This presentation is expected to occur no later than two years after the release of the research funds. The results of the study are expected to be submitted for publication in a peer-reviewed biomedical print or online journal. The HOPA Foundation is to be acknowledged in any presentation or publication for its support of the research.

4. There is no provision for indirect costs in this research grant. A travel budget is expected to be included in the proposal to allow the presentation of the results at the HOPA annual meeting. Additional travel funds should be justified in the context of the needs of the project. Capital equipment purchases are not allowed in this grant.

5. All unused funds remaining from the grant 24 months after the disbursement must be returned to HOPA. The investigator may petition the HOPA Foundation for an extension for use of the funds. This request for an extension must be made at least six months before the expiration of the grant.

James Ewing Foundation of the Society of Surgical Oncology and Susan G. Komen for the Cure 2013 Fall Clinical Investigator Award in Breast Cancer Research

Application deadline: Monday, July 8, 2013

Purpose: To promote patient-oriented research conducted by surgical oncologists in clinical and translational science.

Eligibility

Applicants must be surgical oncologists within 10 years of completion of training

Be full SSO members for at least 6 months prior to application submission to be eligible for the award

Applicants must commit to at least 25% effort for this award

Terms of the Award

The award will be funded for two years at $100,000 ($50,000 per year) beginning October 1, 2013.  The Award concludes September 30, 2015.

The award is given to the sponsoring institution and may be used for partial support of applicant’s salary, research fellows or staff support, tuition, travel(no more than $2,000 per year) and/or supplies. No additional funds are available for paying indirect costs.

A brief year-one progress report with a financial update will be required by September 30, 2014. The JEF reserves the right to withhold the second year of support in the event of unsatisfactory progress.

A final report (not to exceed 4 pages) will be required before September 30, 2015. This should include a summary of the project, abstracts and publications acknowledged as supported by this award, and a financial report. Any unexpended funds from the scholarship are to be reimbursed back to JEF.

A brief (up to 10 minutes) presentation of results will be required at the March 2-5, 2016, SSO Annual Cancer Symposium in Boston, MA. 

The James Ewing Foundation of the Society of Surgical Oncology requests a proposal in which the applicant plays a central role in the conduct of a specific clinical research project. This might include for example a leadership role in a clinical trial, in a prospective cancer outcomes study, or a translational research project related to a prospective clinical trial. The clinical research focus must be hypothesis-driven and must have a direct patient-oriented focus.

Clinical trials may be investigator-initiated, industry-driven or organized by a cooperative group. While the applicant need not be the principal investigator of the trial, nor the lead institutional investigator, the extent to which the applicant is involved in study design and conduct must be clearly articulated. Ideal applicants will be early to mid-career investigators with a track record of peer-reviewed research funding who are seeking additional extramural support to further clinical cancer research. Of note, this award is not intended to serve as a career development award for new investigators seeking to initiate their research careers. The track record of the applicant, scientific merit of the application, novelty and clinical impact of the anticipated results, and resources available to ensure completion of the study will comprise the review criteria.

Questions?

Contact the James Ewing Foundation of the Society of Surgical Oncology, Email:  jef@surgonc.org, or phone 847-427-1400, ext. 111, M-F, 8:30 a.m. - 4:30 p.m. (CT).Address:9525 W. Bryn Mawr Ave., Suite 870 Rosemont, Illinois  60018.  Web: www.surgonc.org

Call for Cancer Projects: Repurposing of Drugs - Breakthrough in Cancer Treatment

Funding Cancer Projects

Reliable Cancer Therapies (RCT) announces € 300 000 for projects repurposing existing drugs for cancer treatment.  The drugs must have been developed and approved for other indication(s). Relevant clinical trial endpoints (cancer survival & tumor response) should be the primary research assessments.

RCT also promotes collaborative research projects between researchers at different universities and/or organisations.

About the Call for Applications

• Medical Degree required for Principal Investigator (PI) or co-PI

• 1 application per PI

• Resubmission is allowed (please indicate the reason for previous decline)

• Set up of proposal:

◦ Application form: maximum 2 pages

◦ in appendix 1: biography & references of the PI and co-PI

◦ in appendix 2: overview of the budget (including salaries, supplies, equipment, patient care costs, and other expenses).

• If your cancer project is selected in the first round, detailled information will be requested for consideration of the final award selections.

• Approved proposals will be supported with a maximum of  € 300 000 for 3 years.

Reliable Cancer Therapies (RCT) is a non-profit organization based in Switzerland that provides research-based information on cancer therapies and selectively funds the development of promising therapies.

RCT investigates information on cancer therapies for evidence to then inform the public about evidence-based cancer treatment choices. We help cancer patients and caregivers to structure and absorb the complex nature of cancer information for their decision-making on registered complementary or alternative therapies.

RCT is continuously looking for cancer therapies that have never been thoroughly examined and consider financing cancer treatments that can be deemed promising based on measurable results.

Application Deadline

Application deadline is June 28, 2013 at 8am GMT. Incomplete or late applications will not be considered.

Please submit applications to Ann-Christine Moenaert (info@reliablecancertherapies.com)

RCT will review the applications internally with the support from our appropriate external experts by August 14, 2013. If the project is selected in the first round, more detailled information will be requested by September 13, 2013.  Final decisions will be made on October 4, 2013.

Contacts at RCT

Please direct any technical questions to Ann-Christine Moenaert (info@reliablecancertherapies.com)

Please contact Gauthier Bouche, MD (info@reliablecancertherapies.com) for any clinical or scientific questions.

Travel Grants for the 4th International Thymic Malignancy Interest Group Annual Meeting (ITMIG 2013)

September 6 - 7, 2013 Bethesda, Maryland

This important Conference will highlight the latest scientific and clinical developments related to the management of thymic malignancies and will bring together established scientists and clinicians from all over the world who have interest in the field of thymic cancers research.

The Conference is pleased to offer travel grants to trainees, residents and fellows.

Eligible Candidates

Trainee, resident or fellow - proof of status required

Submitting and presenting author for an abstract accepted at ITMIG 2013

Benefits

Complimentary full Conference registration

Cash award to help offset travel expenses

Supporting Application Materials

Curriculum Vitae
Recommendation/Supporting Letter from supervisor
Proof of status (trainee, resident, fellow)

How to Apply?

Send application email including supporting materials to itmig2013@icsevents.com by June 14, 2013

Submit abstract via online abstract submission form by June 14, 2013

Terms and Conditions

The organizers reserve the right to

Cancel the scholarship if a selected award winner is not attending in person

Amend the terms and conditions of the scholarship program without notice

Deadlines and Timelines

Application Deadline: June 14, 2013

Notifications: expected to be available end of July 2013

Contact

For any questions or inquries regarding travel grants, please contact the Conference Secretariat at itmig2013@icsevents.com.

Request for Proposal: Desmoid Tumor Research Foundation

Submission deadline for Applications: June 30, 2013.

The Desmoid Tumor Research Foundation, Inc. (“DTRF”) seeks to advance the science related to desmoid tumors by:

• Funding research related to the diagnosis and treatment of desmoid tumors;

• Facilitating and enhancing the dialogue among members of the medical and scientific communities about research related to desmoid tumors;

• Providing informational support for desmoid tumor patients and their families and friends, and heightening awareness of desmoid tumor diagnosis and treatment.

The purpose of this Request for Proposal is to fund research that will advance the current scientific knowledge about desmoid tumors, resulting in the development of new treatment options and bringing us closer to our ultimate goal -- a cure.  Information about DTRF can be found at www.dtrf.org.

Approach

The Desmoid Tumor Research Foundation is the only foundation in the country dedicated to facilitating and funding research for a cure for desmoid tumors.  We fund research that uses cutting-edge science and creative clinical applications, in addition to novel approaches addressing potential leads based on prior research.  Researchers must be willing to collaborate with other scientists and institutions with similar interests.  Research proposals with additional sources of funding support are particularly desirable.

Grant Amounts and Restrictions

• Grants are awarded in amounts of up to $65,000 per year.

• Funds may only be used for personnel, supplies, equipment, and/or services.

• Use of funds for institutional overhead costs is strictly prohibited.

• Use of funds for indirect costs is strictly prohibited.

• Use of funds for project costs that are funded by other sources is strictly prohibited.

• Funding duration is a minimum of 1 year. 

Eligibility for grants:  MD, PhD, or equivalent degree, and sponsorship by an Exempt Organization as defined by Section 501(c)(3) of the Internal Revenue Code (the “Sponsoring Institution”).

American Cancer Society International Fellowships for Beginning Investigators

The objectives of this 12 month ACSBI fellowship, of a value of USD 50,000, are to foster a bi-directional flow of research knowledge, experience, expertise and innovation between countries and to advance the academic career development of beginning cancer investigators through clinical, behavioural and basic research projects.

Closing date: 1 November

The ACSBI fellowship emphasizes the transfer of knowledge from the host institute to others at the home institute. It offers the fellow the opportunity to be mentored by experts in the chosen field, receive hands on experience in clinical, behavioural or basic research, intellectual stimulation, research guidance, narrative transfer and many other opportunities to evolve scientifically and academically.

The goals include not only developing future leaders in cancer research in low/middle income countries, but also facilitating a global effort in cancer prevention and control. This will be done by developing the necessary intellectual infrastructure in home countries (since ACSBI fellows must return to their home institute), encouraging collaborative interactions to facilitate interdisciplinary basic and applied cancer research, and establishing a network of researchers and translational scientists for rapid dissemination of new knowledge and technology in developing and sharing of best practices.

Eligibility

• Be a beginning investigator or clinician in the early stages of their independent investigator career and must possess a terminal, advanced degree with a desire to become an independent investigator

• Applicants are to be in the early phases of their career and no longer under research mentoring.

• Hold an academic university or hospital position with an explicit commitment to return to the home institute

• Conduct the research at not-for-profit institutions. Please note that this is not a first post doctoral fellowship

•Fellowships cannot be granted to candidates who are already physically present at the proposed host institute whilst their applications are under consideration. 

Note: This is not a clinical training fellowship

Call for Proposals: 2013 Yamagiwa-Yoshida Memorial International Cancer Study Grants

The Fellowships team of UICC is pleased to announce the call for proposals for the 2013 Yamagiwa-Yoshida Memorial International Cancer Study Grants. Please note that the application closing date is set to 1st July 2013.

Please find below some key information regarding the fellowship:

WHAT

• 3 months International Fellowship

• Award value of USD 10,000

AIMS

• to initiate, set-up or pursue bilateral cancer research projects with collaborating investigators abroad

• to receive training in advanced experimental research methods and techniques

• to exploit complementary skills and material

WHO

Individuals with:

• scientific or medical qualifications and a minimum of two years postdoctoral experience

• actively engaged in cancer research

• have recent publications in the international peer-reviewed literature

WHY

• 93% of the former grantees consider YY a unique opportunity to carry out international research

• 87% of the former grantees feel their fellowship significantly increased their knowledge and research skills, thus preparing them to better compete internationally

• 73% of grantees have published with their Host mentors as result of their Fellowship whilst 77% of them are still collaborating with their Hosts

• YY experience helped define the research direction of about 80% of the former grantees

• 69% of the former grantees were able to build their own research programme as result of their fellowship

Findings from a UICC survey conducted in 2012, conducted on 139 former grantees and spanning years 1998-2010.

Application closing date: 1st July 2013

UICC Yamagiwa-Yoshida Memorial International Cancer Study Grants (YY) are funded by the Japan National Committee for UICC and Kyowa Hakko Kogyo Co. Ltd., Japan

Should you have any questions, please do not hesitate to contact us at fellows@uicc.org.

Society for Immunotherapy of Cancer Young Investigator Awards Program

SITC's Young Investigator Awards support the growth and achievement of young investigators and up-and-coming researchers in the field of cancer immunotherapy. All awards are supported by the Forward Fund.

Young Investigator Awards

This year, SITC will once again offer 10 Young Investigator Awards in conjunction with the SITC 28th Annual Meeting. Award recipients are chosen based on excellence in quality of research and presentation, the strength of the results and methods, and whether the reported research significantly advances the field. All award recipients will be recognized at the Awards Ceremony at the SITC 28th Annual Meeting.

How to Apply

To be considered for an award, an abstract must be submitted online by July 17, 2013. During the online submission process, you must select the “Apply” button in the “Awards” section to be considered for an award. Award eligibility, abstract guidelines, and instructions for submitting abstracts will be posted on the Abstracts page once finalized.

Award Eligibility

To qualify for a Young Investigator Award, the primary/presenting author must submit an abstract by the deadline and meet the following membership and young investigator criteria:

• Must be a member of SITC current in dues prior to abstract submission.

• Primary/Presenting author must be a Student, Post doctoral research fellow, Clinical fellow, or Junior faculty (instructor or assistant professor) with three (3) or less years (total from all institutions) on staff

• Qualified individual must be listed as both the primary author and presenting author on the abstract.

• Authors selected for oral presentations must be capable and comfortable presenting the abstract to a large audience and answering audience questions.

• Individuals who have previously won the SITC Presidential Award are ineligible for the same award.

Presidential Award

Established in 1991, the SITC Presidential Award serves as recognition to the young investigator deemed to have the most outstanding oral abstract presentation at the SITC Annual Meeting. This recipient is chosen from the four Presidential Travel Award recipients.

SITC Presidential Award recipient will receive:

$1,000 Honorarium

Up to $1,000 in Travel Reimbursement

1-Year Membership with SITC

Commemorative Presidential Award Plaque

Presidential Award Winner Poster Ribbon

Presidential Travel Awards

Four abstracts submitted in any category and authored by young investigators are selected for 20 minute oral presentations during the Presidential Session of the SITC Annual Meeting. Those presenting authors not selected for the SITC Presidential Award will receive a SITC Presidential Travel Award in recognition of their achievement. See past Presidential Travel Award recipients here.

SITC Presidential Travel Award recipients will receive:

Up to $750 in Travel Reimbursement

1-Year Membership with SITC

Presidential Travel Award Certificate

Presidential Travel Award Winner Poster Ribbon

Young Investigator Travel Awards

SITC offers Young Investigator Travel Awards to six young investigators who submitted an abstract for the SITC Annual Meeting. Judging of the abstracts is by a committee of SITC leadership and Annual Meeting organizers.

SITC Travel Award recipients will receive:

Up to $750 in Travel Reimbursement

SITC Travel Award Certificate

SITC Travel Award Winner Poster Ribbon

Questions?

For questions regarding award eligibility, submission deadlines, or other related abstract questions, please contact the SITC Office at 414-271-2456 or info@sitcancer.org.